Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1

Conditions

Breast Neoplasms 349Neoplasms 315Carcinoma, Non-Small-Cell Lung 277Prostatic Neoplasms 221Colorectal Neoplasms 208Lung Neoplasms 177Multiple Myeloma 149Ovarian Neoplasms 136Pancreatic Neoplasms 130Neoplasm Metastasis 123Leukemia, Myeloid, Acute 121Melanoma 104Squamous Cell Carcinoma of Head and Neck 90Recurrence 84Lymphoma 84Carcinoma, Renal Cell 84Lymphoma, Non-Hodgkin 82Endometrial Neoplasms 82Stomach Neoplasms 80Brain Neoplasms 80Precursor Cell Lymphoblastic Leukemia-Lymphoma 79Carcinoma, Hepatocellular 77Head and Neck Neoplasms 71Glioma 70Glioblastoma 70Uterine Cervical Neoplasms 67Urinary Bladder Neoplasms 65Leukemia, Lymphocytic, Chronic, B-Cell 65Sarcoma 63Hematologic Neoplasms 62

Interventions

ebselen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Deafness × 30 days × Clear all
NCT01451853 2026-06-03

SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss

Sound Pharmaceuticals, Incorporated

Phase 2 Withdrawn
Head & NeckThoracic

Ototoxicity, Deafness, Head and Neck Neoplasms, Lung Neoplasms, Tinnitus, Hearing Loss

Data powered by HemOnc (CC BY 4.0) Colophon âš¡